Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma

Clinical Cancer Research

Volumn 23, Issue 18, 2017, Pages 5339-5348

  Delord, Jean Pierre ^a   Robert, Caroline ^b   Nyakas, Marta ^c   McArthur, Grant A ^d   Kudchakar, Ragini ^e   Mahipal, Amit ^f   Yamada, Yasuhide ^g   Sullivan, Ryan ^h   Arance, Ana ⁱ   Kefford, Richard F ^j,k   Carlino, Matteo S ^j   Hidalgo, Manuel ^l   Gomez Roca, Carlos ^a   Michel, Daniela ^m   Seroutou, Abdelkader ^m   Aslanis, Vassilios ^m   Caponigro, Giordano ⁿ   Stuart, Darrin D ⁿ   Moutouh De Parseval, Laure ^m   Demuth, Tim ^m   Dummer, Reinhard ^o   more..

^a Institut Universitaire du Cancer   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e EMORY UNIVERSITY   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY OF SYDNEY   (Australia)

^k MACQUARIE UNIVERSITY   (Australia)

^l Structural Biology and Biocomputing Programme   (Spain)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; ENCORAFENIB; GLUTAMIC ACID; VALINE; VEMURAFENIB; ANTINEOPLASTIC AGENT; CARBAMIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BRAF GENE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; CONFUSION; CONSTIPATION; DARIER DISEASE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM HYPERPLASIA; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERKERATOSIS; HYPERPLASIA; INSOMNIA; KERATOACANTHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; METASTATIC MELANOMA; MOUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECK PAIN; NEURALGIA; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE MODEL; DRUG MONITORING; DRUG SCREENING; GENETICS; KAPLAN MEIER METHOD; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PATHOLOGY; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85029488985     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2923     Document Type: Article

References (35)

1. American Cancer Society. Melanoma skin cancer. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
3. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011;2:135–64.
4. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85.
5. U.S. Food and Drug Administration. Zelboraf (vemurafenib) [package insert]. South San Francisco, CA: Genentech USA, Inc; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202429s006lbl.pdf.
6. European Medicines Agency. Zelboraf (vemurafenib) [summary of product characteristics]. Welwyn Garden City, United Kingdom: Roche; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf.
7. U.S. Food and Drug Administration. Tafinlar (dabrafenib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf.
8. European Medicines Agency. Tafinlar (dabrafenib) [summary of product characteristics]. Camberly, UK: Novartis; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf.
9. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013;49:1297–304.
10. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30–9.
11. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–51.
12. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867–76.
13. Larkin J, Yan Y, McArthur GA, Ascierto PA, Liszkay G, Maio M, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 2015;33 (suppl; abstr 9006).
14. Holderfield M, Nagel TE, Stuart DD. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 2014; 111:640–5.
15. Stuart DD, Li N, Poon DJ, Aardalen K, Kaufman S, Merritt H, et al. Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Res 2012;72:3790.
16. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autopho-sphorylation. Cancer Cell 2013;23:594–602.
17. Gomez-Roca CA, Delord J, Robert C, Hidalgo M, von Moos R, Arance A, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase 1 study. Ann Oncol 2014;25:535P.
18. NCI. common terminology criteria for adverse events (CTCAE). Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
21. Seghers AC, Wilgenhof S, Lebbe C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012;22:466–72.
22. Mackiewicz-Wysocka M, Krokowicz L, Kocur J, Mackiewicz J. Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient. Medicine 2014;93:e157.
23. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16.
24. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205–11.
25. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Results of COLUMBUS part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma. In: Proceedings of the Society for Melanoma Research Congress 2016 Nov 6–9;Boston, MA. Clifton Park (NY): SMRC; 2016.
26. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15: 323–32.
27. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–19.
28. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–703.
29. Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget 2016;7:30453–60.
30. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, et al. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013;31:e215–7.
31. Shailesh FN, Singh M, Tiwari U, Hutchins LF. Vemurafenib-induced bilateral facial palsy. J Postgrad Med 2014;60:187–8.
32. Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2013;2:e00969.
33. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877–88.
34. Kefford R, Miller WH, Tan DS, Sullivan RJ, Long G, Dienstmann R, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK 1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol 2013;31:(suppl; abstr 9029).
35. Sullivan RJ, Weber JS, Patel SP, Dummer R, Miller WH, Cosgrove D, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol 2015;33:(suppl; abstr 9007).